$VRTX
VERTEX PHARMACEUTICALS INC / MA Stock $vrtx

$vrtx Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-Q Financial Statement

#000087532024000198 Filed on August 02, 2024

Income Statement

Concept	2024 Q3	2024 Q2
Revenue	$2.772B	$2.646B
YoY Change	11.61%	6.11%
Cost Of Revenue	$392.6M	$371.9M
YoY Change	23.19%	20.51%
Gross Profit	$2.379B	$2.274B
YoY Change	9.91%	4.08%
Gross Profit Margin	85.84%	85.94%
Selling, General & Admin	$371.8M	$372.2M
YoY Change	40.94%	41.74%
% of Gross Profit	15.63%	16.37%
Research & Development	$875.9M	$966.6M
YoY Change	8.14%	7.86%
% of Gross Profit	36.81%	42.51%
Depreciation & Amortization	$53.20M	$54.00M
YoY Change	26.37%	30.43%
% of Gross Profit	2.24%	2.37%
Operating Expenses	$1.248B	$1.339B
YoY Change	16.19%	15.59%
Operating Profit	$1.116B	-$3.515B
YoY Change	7.53%	-442.43%
Interest Expense	$124.7M	$133.9M
YoY Change	-17.31%	-6.17%
% of Operating Profit	11.17%
Other Income/Expense, Net	-$16.90M	-$23.10M
YoY Change	6.29%	203.95%
Pretax Income	$1.224B	-$3.391B
YoY Change	3.81%	-391.97%
Income Tax	$178.7M	$202.4M
% Of Pretax Income	14.6%
Net Earnings	$1.045B	-$3.594B
YoY Change	0.98%	-492.44%
Net Earnings / Revenue	37.71%	-135.83%
Basic Earnings Per Share	$4.05	-$13.92
Diluted Earnings Per Share	$4.01	-$13.92
COMMON SHARES
Basic Shares Outstanding	258.1M shares	258.1M shares
Diluted Shares Outstanding	261.0M shares	258.1M shares

Balance Sheet

Concept	2024 Q3	2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$6.525B	$5.796B
YoY Change	-45.3%	-48.42%
Cash & Equivalents	$5.239B	$4.580B
Short-Term Investments	$1.285B	$1.215B
Other Short-Term Assets	$449.2M	$575.4M
YoY Change	-16.81%	20.65%
Inventory	$1.080B	$914.6M
Prepaid Expenses
Receivables	$1.751B	$1.656B
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$9.804B	$8.942B
YoY Change	-33.29%	-35.55%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.514B	$1.771B
YoY Change	75.18%	22.4%
Goodwill	$1.088B	$1.088B
YoY Change	0.0%	0.0%
Intangibles	$831.6M	$837.5M
YoY Change	37.77%	38.75%
Long-Term Investments	$4.704B	$4.478B
YoY Change	161.45%	207.6%
Other Assets	$990.2M	$915.6M
YoY Change	108.38%	-51.35%
Total Long-Term Assets	$12.44B	$11.19B
YoY Change	76.89%	72.79%
TOTAL ASSETS
Total Short-Term Assets	$9.804B	$8.942B
Total Long-Term Assets	$12.44B	$11.19B
Total Assets	$22.24B	$20.13B
YoY Change	2.37%	-1.07%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$395.8M	$327.9M
YoY Change	5.29%	-9.67%
Accrued Expenses	$3.220B	$2.940B
YoY Change	10.75%	13.16%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$3.973B	$3.547B
YoY Change	10.38%	5.82%
LONG-TERM LIABILITIES
Long-Term Debt	$114.0M	$346.6M
YoY Change	-70.77%	-14.23%
Other Long-Term Liabilities	$933.3M	$876.8M
YoY Change	7.36%	-21.91%
Total Long-Term Liabilities	$933.3M	$876.8M
YoY Change	7.36%	-42.58%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.973B	$3.547B
Total Long-Term Liabilities	$933.3M	$876.8M
Total Liabilities	$6.609B	$5.357B
YoY Change	26.78%	9.81%
SHAREHOLDERS EQUITY
Retained Earnings	$8.694B	$7.648B
YoY Change	-5.23%	-6.02%
Common Stock	$6.908B	$7.104B
YoY Change	-5.91%	-3.63%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$15.63B	$14.77B
YoY Change
Total Liabilities & Shareholders Equity	$22.24B	$20.13B
YoY Change	2.37%	-1.07%

Cashflow Statement

Concept	2024 Q3	2024 Q2
OPERATING ACTIVITIES
Net Income	$1.045B	-$3.594B
YoY Change	0.98%	-492.44%
Depreciation, Depletion And Amortization	$53.20M	$54.00M
YoY Change	26.37%	30.43%
Cash From Operating Activities	$1.370B	-$3.754B
YoY Change	7.99%	-430.89%
INVESTING ACTIVITIES
Capital Expenditures	$67.70M	$76.70M
YoY Change	66.75%	28.69%
Acquisitions
YoY Change
Other Investing Activities	-$280.3M	-$387.0M
YoY Change	263.55%	58.41%
Cash From Investing Activities	-$348.0M	-$463.7M
YoY Change	195.67%	52.58%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-387.5M	-358.6M
YoY Change	134.85%	-2172.83%
NET CHANGE
Cash From Operating Activities	1.370B	-3.754B
Cash From Investing Activities	-348.0M	-463.7M
Cash From Financing Activities	-387.5M	-358.6M
Net Change In Cash	634.3M	-4.576B
YoY Change	-35.65%	-639.74%
FREE CASH FLOW
Cash From Operating Activities	$1.370B	-$3.754B
Capital Expenditures	$67.70M	$76.70M
Free Cash Flow	$1.302B	-$3.830B
YoY Change	6.05%	-456.37%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	258015301	shares
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	258015301	shares
CY2024Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2645600000	usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2493200000	usd
CY2024Q2	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	128300000	usd
CY2023Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	170300000	usd
CY2024Q2	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	4400000000	usd
	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	4500000000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-3593600000	usd
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	258100000	shares
CY2024Q2	us-gaap	Incremental Common Shares Attributable To Equity Unit Purchase Agreements IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements	0	shares
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	258100000	shares
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-13.92
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-13.92
CY2023Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	77400000	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	400000	usd
CY2024Q2	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	77800000	usd
CY2024Q2	vrtx	Cash Equivalents And Debt Securities Available For Sale CashEquivalentsAndDebtSecuritiesAvailableForSale	1836100000	usd
CY2024Q2	vrtx	Cash Equivalents And Debt Securities Available For Sale Fair Value Disclosure CashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure	1836100000	usd
CY2023Q4	vrtx	Cash Equivalents And Debt Securities Available For Sale CashEquivalentsAndDebtSecuritiesAvailableForSale	7033900000	usd
CY2023Q4	vrtx	Cash Equivalents And Debt Securities Available For Sale Fair Value Disclosure CashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure	7033900000	usd
CY2024Q2	us-gaap	Equity Securities Fv Ni Cost EquitySecuritiesFvNiCost	72100000	usd
	us-gaap	Equity Securities Fv Ni Unrealized Gain EquitySecuritiesFvNiUnrealizedGain	0	usd
	us-gaap	Equity Securities Fv Ni Unrealized Loss EquitySecuritiesFvNiUnrealizedLoss	41500000	usd
CY2024Q2	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	30600000	usd
CY2023Q4	us-gaap	Equity Securities Fv Ni Cost EquitySecuritiesFvNiCost	72100000	usd
CY2023	us-gaap	Equity Securities Fv Ni Unrealized Gain EquitySecuritiesFvNiUnrealizedGain	0	usd
CY2023	us-gaap	Equity Securities Fv Ni Unrealized Loss EquitySecuritiesFvNiUnrealizedLoss	26100000	usd
CY2023Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	46000000.0	usd
CY2024Q2	vrtx	Debtand Equity Securities Cost DebtandEquitySecuritiesCost	5669700000	usd
CY2024Q2	vrtx	Debtand Equity Securities Unrealized Gain DebtandEquitySecuritiesUnrealizedGain	3700000	usd
CY2024Q2	vrtx	Debtand Equity Securities Unrealized Loss DebtandEquitySecuritiesUnrealizedLoss	64900000	usd
CY2024Q2	vrtx	Debtand Equity Securities Fair Value DebtandEquitySecuritiesFairValue	5608500000	usd
CY2023Q4	vrtx	Debtand Equity Securities Cost DebtandEquitySecuritiesCost	3360800000	usd
CY2023Q4	vrtx	Debtand Equity Securities Unrealized Gain DebtandEquitySecuritiesUnrealizedGain	15900000	usd
CY2023Q4	vrtx	Debtand Equity Securities Unrealized Loss DebtandEquitySecuritiesUnrealizedLoss	29700000	usd
CY2023Q4	vrtx	Debtand Equity Securities Fair Value DebtandEquitySecuritiesFairValue	3347000000	usd
CY2024Q2	vrtx	Cash Equivalents Debt And Equity Securities Cost CashEquivalentsDebtAndEquitySecuritiesCost	7505800000	usd
CY2024Q2	vrtx	Cash Equivalents Debt And Equity Securities Unrealized Gain CashEquivalentsDebtAndEquitySecuritiesUnrealizedGain	3700000	usd
CY2024Q2	vrtx	Cash Equivalents Debt And Equity Securities Unrealized Loss CashEquivalentsDebtAndEquitySecuritiesUnrealizedLoss	64900000	usd
CY2024Q2	vrtx	Cash Equivalents Debt And Equity Securities Fair Value CashEquivalentsDebtAndEquitySecuritiesFairValue	7444600000	usd
CY2023Q4	vrtx	Cash Equivalents Debt And Equity Securities Cost CashEquivalentsDebtAndEquitySecuritiesCost	10394700000	usd
CY2023Q4	vrtx	Cash Equivalents Debt And Equity Securities Unrealized Gain CashEquivalentsDebtAndEquitySecuritiesUnrealizedGain	15900000	usd
CY2023Q4	vrtx	Cash Equivalents Debt And Equity Securities Unrealized Loss CashEquivalentsDebtAndEquitySecuritiesUnrealizedLoss	29700000	usd
CY2023Q4	vrtx	Cash Equivalents Debt And Equity Securities Fair Value CashEquivalentsDebtAndEquitySecuritiesFairValue	10380900000	usd
CY2024Q2	vrtx	Cash Equivalents Debt And Equity Securities Fair Value CashEquivalentsDebtAndEquitySecuritiesFairValue	7444600000	usd
CY2023Q4	vrtx	Cash Equivalents Debt And Equity Securities Fair Value CashEquivalentsDebtAndEquitySecuritiesFairValue	10380900000	usd
CY2024Q2	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	usd
CY2023Q2	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	usd
	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0	usd
	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0	usd
CY2024Q2	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0	usd
CY2023Q2	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0	usd
CY2024Q2	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	4600000000	usd
CY2024Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	23400000	usd
CY2024Q2	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	382400000	usd
CY2024Q2	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	3500000	usd
CY2024Q2	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-12700000	usd
CY2023Q2	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	9200000	usd
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-15400000	usd
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-900000	usd
CY2024Q2	us-gaap	Equity Securities Without Readily Determinable Fair Value Downward Price Adjustment Cumulative Amount EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount	24300000	usd
	us-gaap	Oci Before Reclassifications Net Of Tax Attributable To Parent OciBeforeReclassificationsNetOfTaxAttributableToParent	43900000	usd
	us-gaap	Reclassification From Aoci Current Period Net Of Tax Attributable To Parent ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent	7100000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	36800000	usd
	us-gaap	Oci Before Reclassifications Net Of Tax Attributable To Parent OciBeforeReclassificationsNetOfTaxAttributableToParent	-16900000	usd
	us-gaap	Reclassification From Aoci Current Period Net Of Tax Attributable To Parent ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent	23700000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-40600000	usd
CY2024Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2645600000	usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2493200000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	5336200000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	4868000000	usd
CY2024Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-23100000	usd
CY2023Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1600000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-54300000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2900000	usd
CY2024Q2	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	112100000	usd
CY2023Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	78700000	usd
CY2024Q2	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	657600000	usd
CY2023Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	525100000	usd
CY2024Q2	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	144900000	usd
CY2023Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	135000000.0	usd
CY2024Q2	us-gaap	Inventory Net InventoryNet	914600000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	738800000	usd
CY2024Q2	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	2800000	usd
CY2023Q2	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	600000	usd
	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	3900000	usd
	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	1000000.0	usd
CY2024Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	154200000	usd
CY2023Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	119300000	usd
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	346100000	usd
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	241700000	usd
CY2024Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	154200000	usd
CY2023Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	119300000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	346100000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	241700000	usd
CY2024Q2	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	80700000	usd
CY2023Q2	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	31300000	usd
	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	159700000	usd
	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	71900000	usd
CY2024Q2	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	73500000	usd
CY2023Q2	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	88000000.0	usd
	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	186400000	usd
	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	169800000	usd
CY2023Q1	srt	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	3000000000	usd
	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	1100000	shares
	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	500000	shares
	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	456200000	usd
	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	161100000	usd
CY2024Q2	us-gaap	Stock Repurchase Program Remaining Authorized Repurchase Amount1 StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1	2100000000	usd
CY2024Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3391200000	usd
CY2023Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	1161500000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2112100000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	2053000000	usd
CY2024Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	202400000	usd
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	245800000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	381900000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	437500000	usd
CY2024Q2	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.060
CY2023Q2	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.212
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.181
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.213
CY2024Q2	us-gaap	Income Tax Reconciliation Nondeductible Expense Research And Development IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment	4400000000	usd
	us-gaap	Income Tax Reconciliation Nondeductible Expense Research And Development IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment	4400000000	usd
CY2024Q2	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	309300000	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	288700000	usd
CY2024Q2	vrtx	Indemnification Claims IndemnificationClaims	0	usd
CY2023Q4	vrtx	Contingent Liabilities ContingentLiabilities	0	usd
CY2024Q2	vrtx	Contingent Liabilities ContingentLiabilities	0	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10369100000	usd
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4580100000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10504000000	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10151100000	usd
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	3200000	usd
CY2024Q2	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	10900000	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	8000000.0	usd
CY2023Q2	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	2300000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10372300000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4591000000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10512000000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10153400000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	295000000.0	usd
CY2024Q2	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q2	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0000875320-24-000198-index-headers.html	Edgar Link	pending
0000875320-24-000198-index.html	Edgar Link	pending
0000875320-24-000198.txt	Edgar Link	pending
0000875320-24-000198-xbrl.zip	Edgar Link	pending
a2024q210-qexhibit101.htm	Edgar Link	pending
a2024q210-qexhibit311.htm	Edgar Link	pending
a2024q210-qexhibit312.htm	Edgar Link	pending
a2024q210-qexhibit321.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
vrtx-20240630.htm	Edgar Link	pending
vrtx-20240630.xsd	Edgar Link	pending
vrtx-20240630_g1.jpg	Edgar Link	pending
vrtx-20240630_cal.xml	Edgar Link	unprocessable
vrtx-20240630_def.xml	Edgar Link	unprocessable
vrtx-20240630_lab.xml	Edgar Link	unprocessable
vrtx-20240630_pre.xml	Edgar Link	unprocessable
vrtx-20240630_htm.xml	Edgar Link	completed
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$VRTX
VERTEX PHARMACEUTICALS INC / MA Stock $vrtx

2024 Q3 Form 10-Q Financial Statement

#000087532024000198 Filed on August 02, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VRTX VERTEX PHARMACEUTICALS INC / MA Stock $vrtx

2024 Q3 Form 10-Q Financial Statement

#000087532024000198 Filed on August 02, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VRTX
VERTEX PHARMACEUTICALS INC / MA Stock $vrtx